PerkinElmer IVIS Spectrum CT

PerkinElmer IVIS 光谱 CT

• 批准号: 8826454
• 负责人: Judy Drazba
• 金额: $ 59.97万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-13 至 2016-02-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8826454
• 关键词: 9 year old; Acute; Affect; Animal Model; Animals; Biomedical Research; Cardiovascular Diseases; Clinic; Clinical Medicine; Communities; Contract Services; Costs and Benefits; Development; Equipment; Funding; Glioblastoma; Grant; Health; Image; Institutes; Maintenance; Mus; Pathway interactions; Recording of previous events; Research; Research Infrastructure; Research Institute; Research Personnel; Resolution; Running; Safety; Supervision; System; Training; United States National Institutes of Health; Wages; X-Ray Computed Tomography; animal imaging; bioimaging; clinical application; experience; flexibility; improved; instrument; member; microbiome; pre-clinical; programs; quantitative imaging; research facility; research study; response; translational medicine

 DESCRIPTION (provided by applicant): The Imaging Core of the Cleveland Clinic Lerner Research Institute (LRI) and a group of sixteen investigators (12 NIH-funded) request funds to purchase a PerkinElmer IVIS Spectrum CT. It will be placed in the Small-Animal Imaging section of the well-established Imaging Core where it will be broadly used in the pre-clinical and translational medicine research program at Cleveland Clinic. In its twenty years the Core has provided leading-edge imaging equipment and expertise for the Cleveland Clinic research community. It is a strong and successful Core in a significant research facility. As the calculatio of the costs and benefits of research funding grows more acute, investigators are seeking a more immediate pathway from basic biomedical research to clinical application - often with wider and more frequent reliance on animal model studies. The instrument here requested is fundamental to such research, and essential to the projects presented herein. This integrated, multi-modal system will provide us a new and much-needed level of imaging capability and flexibility, including the possibility of Computed Tomography (an option previously available to very few researchers on a 9-year-old GE Explorer Locus RS that is now failing and is officially obsolete). The improved sensitivity, resolution, and three-dimensional quantitative imaging of the IVIS Spectrum CT will allow for a broad range of applications envisioned by the studies included here: for example, the impact of the gut microbiome on cardiovascular disease or the factors that modulate glioblastoma development, progression, and response to therapy. The need of the included investigators for this instrument is further underscored by the decision of our Institute to enhance animal health and experimental safety by creating a mouse barrier facility. This is a costly project, already underway. It significantly affects our investigators' experiments, since they will have to take place inside the barrier. Because of this, the new facility will include an Imaging Suite-with a room designated specifically for this instrument. The new system will be under the Imaging Core's management, assuring its supervision and support by a skilled staff. Dr. Judith Drazba, Core Director, has over thirty years' experience in biomedical imaging, twenty of them running this facility. Dr. Dolores Hambardzumyan, co-PI on this grant, has ten years of intensive experience in a full range of small animal imaging. Other members of the Imaging Core staff will assist with user training, and equipment troubleshooting and maintenance. Finally, the LRI has a long history of strong support for centralized facilities and will continue its commitment to the Imaging Core by providing funds for salary support, service contracts, and infrastructure.

 描述(由申请人提供)：克利夫兰临床勒纳研究所(LRI)的成像核心和一个由16名研究人员(12名NIH资助)组成的小组申请资金购买PerkinElmer IVIS Spectrum CT。它将被放置在完善的成像核心的小动物成像部分，在那里它将被广泛用于克利夫兰诊所的临床前和转化医学研究计划。在其二十年的历史中，Core为克利夫兰临床研究界提供了先进的成像设备和专业知识。在重要的研究机构中，它是一个强大而成功的核心。随着研究资金的成本和收益的计算变得更加尖锐，研究人员正在寻找从基础生物医学研究到临床应用的更直接的途径--通常是更广泛和更频繁地依赖动物模型研究。这里要求的仪器是这种研究的基础，对这里提出的项目也是必不可少的。这个集成的多模式系统将为我们提供一个新的、急需的成像能力和灵活性水平，包括计算机断层扫描(这是一个以前只有很少的研究人员可以使用的选项，使用已有9年历史的GE Explorer Locus RS，现在它正在失败，并已正式过时)。IVIS Spectrum CT的灵敏度、分辨率和三维定量成像的改进将使本文所包括的研究设想的广泛应用成为可能：例如，肠道微生物群对心血管疾病的影响，或调节胶质母细胞瘤发生、进展和治疗反应的因素。我们研究所决定通过建立老鼠屏障设施来加强动物健康和实验安全，进一步强调了纳入研究人员对该仪器的需求。这是一个耗资巨大的项目，已经在进行中。这极大地影响了我们的研究人员的实验，因为它们将不得不在屏障内进行。正因为如此，新的设施将包括一个成像套件--有一个专门为这台仪器指定的房间。这个 新系统将在成像核心的管理下，确保其由熟练的工作人员进行监督和支持。核心总监朱迪思·德拉兹巴博士在生物医学成像领域拥有30多年的经验，其中20人管理着这个设施。Dolores Hambardzumyan博士是这笔赠款的联合PI，在小动物全方位成像方面拥有十年的密集经验。成像核心工作人员的其他成员将协助用户培训、设备故障排除和维护。最后，LRI长期以来一直大力支持中央设施，并将通过为工资支持、服务合同和基础设施提供资金来继续其对成像核心的承诺。

项目成果

SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells.

• DOI: 10.15252/emmm.202012291
• 发表时间: 2020-12-07
• 期刊: EMBO molecular medicine
• 影响因子: 11.1
• 作者: Tao W;Zhang A;Zhai K;Huang Z;Huang H;Zhou W;Huang Q;Fang X;Prager BC;Wang X;Wu Q;Sloan AE;Ahluwalia MS;Lathia JD;Yu JS;Rich JN;Bao S
• 通讯作者: Bao S

Novel INHAT repressor drives glioblastoma growth by promoting ribosomal DNA transcription in glioma stem cells.

新型 INHAT 阻遏蛋白通过促进神经胶质瘤干细胞中的核糖体 DNA 转录来驱动胶质母细胞瘤生长。

• DOI: 10.1093/neuonc/noac272
• 发表时间: 2023
• 期刊: Neuro-oncology
• 影响因子: 15.9
• 作者: Tao,Weiwei;Lei,Hong;Luo,Wenlong;Huang,Zhi;Ling,Peng;Guo,Mengyue;Wan,Lihao;Zhai,Kui;Huang,Qian;Wu,Qiulian;Xu,Shutong;Zeng,Liang;Wang,Xiuxing;Dong,Zhiqiang;Rich,JeremyN;Bao,Shideng
• 通讯作者: Bao,Shideng

Cathepsin K-targeted sub-micron particles for regenerative repair of vascular elastic matrix.

• DOI: 10.1016/j.actbio.2017.01.032
• 发表时间: 2017-04-01
• 期刊: Acta biomaterialia
• 影响因子: 9.7
• 作者: Jennewine B;Fox J;Ramamurthi A
• 通讯作者: Ramamurthi A

Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells.

• DOI: 10.1038/s43018-021-00267-9
• 发表时间: 2021-11
• 期刊: Nature cancer
• 影响因子: 22.7
• 作者: Zhai K;Huang Z;Huang Q;Tao W;Fang X;Zhang A;Li X;Stark GR;Hamilton TA;Bao S
• 通讯作者: Bao S

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.

• DOI: 10.1084/jem.20151673
• 发表时间: 2017-01
• 期刊: The Journal of experimental medicine
• 作者: Fang X;Zhou W;Wu Q;Huang Z;Shi Y;Yang K;Chen C;Xie Q;Mack SC;Wang X;Carcaboso AM;Sloan AE;Ouyang G;McLendon RE;Bian XW;Rich JN;Bao S
• 通讯作者: Bao S